Attached files
| file | filename |
|---|---|
| EX-10.13 - EX-10.13 - Frequency Therapeutics, Inc. | freq-ex1013_758.htm |
| 10-K - 10-K - Frequency Therapeutics, Inc. | freq-10k_20191231.htm |
| EX-32.2 - EX-32.2 - Frequency Therapeutics, Inc. | freq-ex322_6.htm |
| EX-31.2 - EX-31.2 - Frequency Therapeutics, Inc. | freq-ex312_8.htm |
| EX-31.1 - EX-31.1 - Frequency Therapeutics, Inc. | freq-ex311_9.htm |
| EX-23.1 - EX-23.1 - Frequency Therapeutics, Inc. | freq-ex231_1116.htm |
| EX-21.1 - EX-21.1 - Frequency Therapeutics, Inc. | freq-ex211_757.htm |
| EX-10.5.1 - EX-10.5.1 - Frequency Therapeutics, Inc. | exhibit10_51.htm |
| EX-4.3 - EX-4.3 - Frequency Therapeutics, Inc. | freq-ex43_875.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Frequency Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David L. Lucchino, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 26, 2020 |
|
By: |
/s/ David L. Lucchino |
|
|
|
|
David L. Lucchino |
|
|
|
|
President and Chief Executive Officer |